Cilliers T, Patience T, Papathanasopolous MA, Morris L; IAS Conference on HIV Pathogenesis and Treatment (2nd : 2003 : Paris, France).
Antivir Ther. 2003; 8 (Suppl.1): abstract no. 97.
National Institute for Communicable Diseases, Johannesburg, South Africa
T-20 represents the first in a new class of antiretroviral agents targeting the entry stage of the viral life cycle. It is a 36 amino acid peptide, which binds to the HR1 region of gp41 preventing fusion of viral and cellular membranes. The effectiveness of T-20 for HIV-1 subtype B isolates is well-defined, whereas less is known regarding its activity against HIV-1 subtype C isolates. HIV-1 subtype C now accounts for more than half the new infections globally and, as such, these isolates should be included in an evaluation of any new antiviral compounds. We analyzed the ability of T-20 to inhibit HIV-1 subtype C isolates in a PBMC infectivity assay where p24 antigen was measured between days 4-8. This included 13 R5, three R5X4 and two X4 isolates. T-20 at 1 microg/ml was effective against all isolates with most showing greater than 90% inhibition. All isolates had the amino acids GIV at positions 36-38 in gp41, which are associated with sensitivity to T-20. One X4 had a GVV motif but this did not affect its sensitivity. These data suggest that T-20 appears to be effective against HIV-1 subtype C isolates and may be useful for treating patients infected with this subtype.
Publication Types:
Keywords:
- Anti-HIV Agents
- Anti-Retroviral Agents
- Antiviral Agents
- CASP4 protein, human
- Caspases
- HIV Fusion Inhibitors
- HIV Protease Inhibitors
- HIV-1
- Humans
- Reverse Transcriptase Inhibitors
- therapy
Other ID:
UI: 102262422
From Meeting Abstracts